Clinical Research
Copyright ©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 21, 2005; 11(43): 6823-6827
Published online Nov 21, 2005. doi: 10.3748/wjg.v11.i43.6823
Table 4 Evaluation of nephrotoxicity
Treatment regimen
Cefotaxime(%)Amikacin(%)P
Number of patients1918
Renal impairment (%)22 (10.5)2 (11.1)NS
Urinary β2-microglobulin (mg/L)
Before treatment1402 ± 801220 ± 392NS
3 d after initiation1779 ± 2465612 ± 814NS
2 d after withdrawal1126 ± 119173 ± 44NS
increase > 2 000 mg/L (%)21 (5.3)1 (5.6)NS